NeoGenomics to Participate in NCI-MATCH
October 5, 2018NeoGenomics announced today its participation as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice, or NCI-MATCH, precision medicine cancer treatment clinical trial.
Launched in 2015, NCI-MATCH is testing the efficacy of cancer treatments that are selected based on the genomic markers driving patients’ tumors, regardless of cancer type. Earlier this month, Strata Oncology announced its participation in the trial.
Source: https://www.genomeweb.com/molecular-diagnostics/neogenomics-participate-nci-match